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Abstract
Background: We investigated the patient- and treatment-system dependent factors affecting
treatment outcome in a two-year cohort of all treated culture-verified pulmonary tuberculosis (TB)
cases to establish a basis for improving outcomes.
Methods: Medical records of all cases in 1995 – 1996 were abstracted to assess outcome of
treatment. Outcome was divided into three groups: favourable, death and other unfavourable.
Predictors of unfavourable outcome were assessed in univariate and multivariate analysis.
Results: Among 629 cases a favourable outcome was achieved in 441 (70.1%), 17.2% (108) died
and other unfavourable outcome took place in 12.7% (80). Significant independent risk factors for
death were male sex, high age, non-HIV -related immunosuppression and any other than a
pulmonary specialty being responsible for stopping treatment. History of previous tuberculosis was
inversely associated with the risk of death. For other unfavourable treatment outcomes, significant
risk factors were pause(s) in treatment, treatment with INH+RIF+EMB/SM, and internal medicine
specialty being responsible at the end of the treatment.
Conclusion: We observed a significant association with unfavourable outcome for the specialty
responsible for treatment being other than pulmonary, but not for the volume of cases, which has
implications for system arrangements. Poor outcomes associated with immunosuppression and
advanced age, with frequent comorbidity, stress a low threshold of suspicion, availability of rapid
diagnostics, and early empiric treatment as probable approaches in attempting to improve
treatment outcomes in countries with very low incidence of TB.
Background
Early diagnosis of tuberculosis and effective treatment are
the key elements in reduction of transmission of infection
and finally achieving elimination of TB [1]. World Health
Organization (WHO) has set the international target
value for a favourable treatment outcome at 85% [2].
Treatment outcome monitoring is a core part of surveil-
lance necessary to succeed in tuberculosis elimination [3].
The WHO has published a recommendations for assessing
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the outcome of tuberculosis treatment in 1990's [4],
revised recently [5,6].
In many industrialized countries with good treatment
facilities and a secured supply of drugs free of charge for
patients, treatment results have not reached the targets set
by WHO [7-18]. The main reason for this is the high rate
of death as an unfavourable outcome, frequently with
much comorbidity from other diseases. Incomplete treat-
ment carries a risk of development of resistance, increased
disease transmission, and increased morbidity and mor-
tality [19]. In our earlier report from Finland, a favourable
outcome was reached in only 65%, death being the out-
come in as much as 19%, and defaulting, transferring out
or physician's decision to stop treatment early being rea-
sons for other unfavourable outcomes in 12% of the cases
[20].
The specific reasons for unsuccessful outcomes are impor-
tant in order to improve treatment systems. In a recent
outcome analysis from Norway, where the large majority
of TB cases are in immigrants, only high age and isoniazid
(INH) resistance were significant risk factors for non-suc-
cessful outcome [21]. In earlier studies, high age, alcohol-
ism, HIV-infection, male sex and immigration have been
associated with unfavourable outcomes [7,12,22].
In low incidence countries, many of the clinical units
treating tuberculosis patients have small and decreasing
numbers of patients. This necessitates an assessment of
the need to concentrate patients in fewer units to retain
the level of experience sufficient for successful outcomes.
There is varying evidence from assessments made in other
areas of complex treatments, such as leukaemia, AIDS,
demanding surgery and myocardial infarction, that the
volume of treatments has an effect on the outcome
[23,24]. It is possible that treatment organisation and
implementation in bigger hospitals are more effective and
up to date [25]. However, there is little data available on
whether the volume of tuberculosis patients treated
would associate with favourable outcomes.
We assessed the patient and treatment system dependent
factors affecting treatment outcome in a national, popula-
tion-based two-year cohort of all culture-verified pulmo-
nary tuberculosis cases in Finland, with a TB incidence of
12,5 per 100 000 per year during the study period, to
establish a basis for improving the proportion of favoura-
ble outcomes.
Methods
Study cohort, case definitions and data collection
The method of identifying all culture-confirmed tubercu-
losis cases in Finland, with the first positive culture sam-
ple date between January 1st, 1995, to December 31st,
1996 (N = 1059), present in either the National Infectious
Disease Register (NIDR) or through a separate query to all
microbiological laboratories has been described else-
where [26].
A case of tuberculosis was defined for the study as pulmo-
nary using the case definition of NIDR, i.e. as a culture
finding for M. tuberculosis in sputum or bronchoalveolar
lavage (BAL), or as a culture finding for M. tuberculosis
from another sample type in a case with sputum smear
positive for acid fast bacilli. With this definition, 737 (70
% of the whole cohort) cases with pulmonary tuberculosis
were identified. Species identification for Mycobacterium
tuberculosis was carried out in every case. There were alto-
gether 660 isolations of mycobacteria other than M.
tuberculosis during the study period. Only culture posi-
tive cases were taken into the study in order to be able to
study only the fully confirmed cases.
Out of the 737 pulmonary tuberculosis cases, complete
medical records were available from 711 (96%). Among
these 711 cases, twenty-two (3.1%) had previously been
treated for tuberculosis after the year 1970, and were
excluded from the outcome analysis as re-treatment cases.
Of the 689 cases, 33 were still on treatment at 12 months,
and were also excluded from the analysis. Of the remain-
ing 656 cases, 27 were not treated, among them 19
(70.4%) were men and 8 (29.6%) women. Of this group,
with a median age of 82.0 years, 24 died before treatment
and 3 were left untreated. Those without treatment were
excluded from the main analysis of 629 actually treated
cases (Figure 1).
Definitions of treatment
Tuberculosis treatment was initiated in and supervised by
the pulmonary departments of public hospitals in the
great majority of cases. Chemotherapy actually given to
each patient, according to record review, was grouped into
six categories (Table 1). Definitions for the grouping were
based on the national recommendations in Finland fol-
lowing the recommendations by WHO, ATS and BTS [27-
32]. We have previously described the treatment grouping
in detail [20]. Duration of treatment was assessed only for
standard treatment groups (A – D). In the combination of
isoniazid, rifampicin and pyrazinamide (HRZ) with or
without an extra drug, the recommended duration of
treatment was defined as 167 – 213 days. For the combi-
nation isoniazid, rifampicin and ethambutol (HRE) or
isoniazid, rifampicin and streptomycin (HRS) ± extra
drug, the recommended duration of treatment was
defined as 243 – 304 days. Pauses of chemotherapy were
recorded only when lasting at least one week, and calcu-
lated only for standard treatments.BMC Public Health 2007, 7:291 http://www.biomedcentral.com/1471-2458/7/291
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Composition of the national study cohort of culture-confirmed pulmonary tuberculosis cases treated at least 24 hours included  in analysis Figure 1
Composition of the national study cohort of culture-confirmed pulmonary tuberculosis cases treated at least 24 hours included 
in analysis.
Table 1: Definitions used in describing the treatment given to the cases in a national cohort of patients with pulmonary tuberculosis
Treatment group Drugs used in intensive 
phase
Duration of 
intensive phase [days]
Drugs used in 
continuation phase
Total duration of 
treatment [months]
Standard treatment A isoniazid + rifampicin + 
pyrazinamide
At least 54 isoniazid + rifampicin At least 5 1/2
Standard treatment B isoniazid + rifampicin + 
ethambutol or streptomycin
At least 54 isoniazid + rifampicin At least 8
Standard treatment 
with short intensive 
phase C
isoniazid + rifampicin + 
pyrazinamide or ethambutol or 
streptomycin
Less than 54 isoniazid + rifampicin At least 5 1/2 for A At 
least 8 for B
Standard treatment D ≥ 4 tuberculosis drugs, including 
the drugs in Standard treatment 
A or B
At least 54 isoniazid + rifampicin ± any 
other anti-tuberculosis drug(s)
At least 5 1/2 for A At 
least 8 for B
Other combination of 
tuberculosis drugs
Non-standard combinations of 
tuberculosis drugs, excluding 
the combinations above
NA2 Any combination of 
antituberculosis drugs
NA
Ineffective treatment One antituberculosis drug used 
alone or in combination with a 
drug with limited 
antituberculosis activity1
NA NA NA
1E.g. fluoroquinolones
2NA = not applicableBMC Public Health 2007, 7:291 http://www.biomedcentral.com/1471-2458/7/291
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Definitions of outcome
The categories of WHO/EuroTB recommendation [6] for
outcome monitoring are cure, treatment completed, fail-
ure, death, treatment interrupted (default), transfer out,
and on treatment at 12 months. The duration of the fol-
low up period is defined as 12 months from the beginning
of the treatment or the date of diagnosis, and the first out-
come registered as final.
The WHO/EuroTB category 'treatment interrupted'
includes all treatment courses which remained shorter
than defined above, whether caused by a patient or by a
treating physician. For analysing these two separately, we
divided 'treatment interrupted' into 'physician's decision
to stop early' and 'default' for interruptions due to patient
only [20]. The outcome was recorded as 'death', if the case
died before starting the treatment (not included in the
current analysis), during the treatment, or the date of
death was within 14 days after cessation of the anti-TB
drugs.
The outcome was categorized as favourable in cases of
cure and treatment completed, and as unfavourable in
cases of failure, death, default, physician's decision to stop
early and transfer out.
Definitions of origin, social and medical risk factors
A case was defined as immigrant if the country of birth
was not Finland or, in the absence of country of birth, the
nationality was other than Finnish. Immunosuppressive
treatment was defined as corticosteroid treatment (>40
mg per day of any duration, or any daily dose with dura-
tion exceeding one month), cytotoxic or cyclosporine
treatment, or radiation therapy during the preceding year.
For inclusion in the group of social risk factors, a case
should have a history of alcohol abuse, unemployment,
imprisonment or homelessness recorded in patient
records. Diabetes was defined as juvenile or adult onset
disease on medication.
Definitions of characteristics of treatment system
Specialty responsible for treatment was that of the unit
treating patient as an inpatient or outpatient. Change of
specialty included any change from one speciality to
another during treatment.
Ethical review
The ethics approval for this study was acquired from the
National Research and Development Centre for Welfare
and Health.
Statistical methods
We used multinomial logistic regression model to assess
the relationships between all potential predictors, listed in
the univariate analysis, and a 3-class outcome variable, in
which reference class was favourable outcome. To the
final model significant predictors were selected using for-
ward stepwise methods. Any variable whose univariable
test had a p-value <0.20 was included in the multivariable
analysis. P-values under 5% were considered as signifi-
cant. For univariate results Chi squared test and Fisher's
exact test were used.
Results
In the study cohort of 629 cases, 386 (61.4%) were men
and 243 (38.6%) women. The mean age was 62.9 years,
the median 67.2. The proportion of cases aged ≥65 years
was 339 (53.9%). The proportion of immigrants was
4.1% (26 cases), mainly from developing countries (Table
2). Only two patients in the cohort had HIV-coinfection.
There were no prisoners.
A favourable outcome was achieved in 441 (70.1%) of the
cases, consisting of those cured 199 (31.6%) and treat-
ment completed 242 (38.5%). There were no treatment
failures in the cohort. The proportion of cases defaulting
or transferring out was 32 (5.1 %). For 48 (7.6%) cases,
treatment was stopped prematurely by physician. Death
was the outcome in 17.2 % (108/629) cases.
In univariate analysis, patient-related risk factors which
were significantly associated (p < 0.05) with death, were
age ≥65 years, social risk factor, immunosuppression and
malignancy (Table 2). Treatment system -related risk fac-
tors which were significantly associated with death were
the specialty of the treating unit (internal medicine, gen-
eral medicine in primary care), less than five treated cases
per year per unit, ineffective treatment combination and
change in the treatment group (Table 3). The only statisti-
cally significant patient-related personal risk factor associ-
ation for other unfavourable outcome (i.e. transfer out,
default or physician's decision to stop early), was immi-
gration (Table 2). Treatment system -related significant
risk factors for other unfavourable outcome were internal
medicine as the last treating specialty, standard treatment
B and pause(s) during treatment (Table 3). For all unfa-
vourable outcomes together, i.e. death and other unfa-
vourable outcome combined, significant predictors in
univariate analysis were gender, immunosuppression,
malignancy, earlier TB, any other than a pulmonary unit
being responsible at the end of the treatment, treatment
group, pause(s) during treatment, less than five treated
cases per year per unit and any change of specialty respon-
sible for treatment.
Significant independent risk factors for death in multino-
mial logistic regression model were male sex, high age,
immunosuppression and any other than a pulmonary
specialty being responsible at the end of the treatment.
History of previous tuberculosis was inversely associatedBMC Public Health 2007, 7:291 http://www.biomedcentral.com/1471-2458/7/291
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with the risk of death (p = 0.044). For other unfavourable
treatment outcomes, significant risk factors were pause(s)
in treatment, treatment group B and internal medicine
being responsible at the end of the treatment (Table 4).
For death and other unfavourable outcomes together, sig-
nificant risk factors in the multinomial logistic regression
model were male sex (p = 0.005), high age (p = 0.03),
pause(s) in treatment (p < 0.001), treatment group other
than A (p = 0.003) and any other than a pulmonary spe-
cialty being responsible for ending the treatment (p <
0.001). Earlier TB was a significant factor for favourable
outcome (p = 0.012).
When we analysed all 656 cases in the cohort with known
outcome, including those 27 without treatment, the asso-
ciations observed in univariate and multivariate analysis
as significant were the same as with the 629 cases of the
presented analysis.
Discussion
We analysed a large 2-year national cohort of culture-
proven pulmonary tuberculosis cases for patient- and
treatment-system related risk factors of unfavourable out-
come. Apart from previously known patient-related risk
factors for an unfavourable outcome, we observed a sig-
nificant association with unfavourable outcome for the
specialty responsible for treatment being other than pul-
monary, but not for the volume of cases that the unit
treated per year.
Due to the strictly controlled data collection process and
high coverage, as reported previously [26], the data is
highly representative. TB treatment recommendations
and treatment organisation, as well as the proportion of
foreign born, the age distribution and the case fatality rate
have all remained unchanged since the study period in
1995–1996, making the analysis and conclusions valid
for the present.
Due to relatively small number of deaths, the power of the
study to investigate death as outcome was limited. The
study was retrospective. Therefore, despite the meticulous
conduct, it is possible that not all factors such as co-mor-
bid conditions were recorded in the case notes.
Due to the fact that the TB patients in Finland are excep-
tionally old [13], contributing to the risk of death in sev-
eral ways, we analysed separately the risk factors
associated with death as outcome, as well as the risk fac-
tors for other unfavourable outcomes which may better
reflect system features that may be amenable for improve-
ment. Increasing age was strongly associated with death,
contributing to the high case fatality ratio observed, and
the major reason for not reaching the WHO targets for
favourable outcomes. High age has been previously
reported to be a risk factor for death, partly due to increas-
ing comorbidities as well as the general physiological
deterioration with age [7,12,21,22], because of which
close monitoring of treatment in older patients is neces-
sary. In older population it is often difficult to determine
Table 2: Univariate analysis of the association of patient – related characteristics with an unfavourable outcome in 629 cases treated 
for at least 24 hours
Variable Total Death Other unfavourable
N N OR (95% CI) p N OR (95% CI) p
Sex female 243 35 1 30 1
male 386 73 1.41 (0.90–2.204) 0.15 50 1.13 (0.69–1.84) 0.71
Age group 0 – 44 118 6 1 20 1
45 – 64 172 18 2.12 (0.81–5.56) 0.12 24 0.85 (0.44–1.63) 0.62
65 - 339 84 5.89 (2.48–13.94) <0.001 36 0.75 (0.42–1.38) 0.36
TB history no 570 101 1 76 1
yes 59 7 0.57 (0.25–1.29) 0.21 4 0.43 (0.15–1.23) 0.15
Social risk factor1 no 330 76 1 33 1
yes 295 32 0.43 (0.27–0.68) <0.001 46 1.42 (0.87–2.30) 0.18
Birthplace or nationality Finland 603 107 1 72 1
abroad 26 1 0.23 (0.031–1.77) 0.22 8 2.77 (1.15–6.66) 0.040
Immunosuppression no 548 78 1 76 1
yes 81 30 3.22 (1.92–5.42) <0.001 4 0.44 (0.15–11.3) 0.15
Malignancy2 no 613 102 1 77 1
yes 15 6 4.26 (1.35–13.46) 0.017 3 2.82 (0.69–11.5) 0.15
Diabetes no 537 86 1 73 1
yes 92 22 1.54 (0.86–2.63) 0.14 7 0.58 (0.25–1.31) 0.21
1Information missing for four cases
2Information missing for one case
Significant p-values are darkened.B
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Table 3: Univariate analysis of the association of treatment system – related characteristics with an unfavourable outcome in 629 cases treated for at least 24 hours
Variable Total Death Other unfavourable
N N OR (95% CI) p N OR (95% CI) p
Specialty responsible for starting treatment1 pulmonary 579 90 1 76 1
internal medicine 34 11 2.52 (1.17–5.45) 0.018 3 0.82 (0.24–2.81) 0.75
general medicine 6 2 3.06 (0.50–18.58) 0.22 61 1.81 (0.18–17.65) 0.61
other 9 4 3.67 (0.97–13.34) 0.056 0 - -
Specialty responsible for ending treatment2 pulmonary 531 61 1 67 1
internal medicine 28 17 18.72 (7.10–49.23) <0.001 5 5.01 (1.49–16.89) 0.009
general medicine 47 22 6.92 (3.59–13.34) <0.001 4 1.15 (0.38–3.44) 0.81
other 15 6 4.96 (1.66–14.77) 0.004 1 0.75 (0.093–6.11) 0.79
Change of specialty responsible for treatment2 no 530 66 1 71 1
yes 91 40 5.29 (3.21–8.72) <0.001 6 0.74 (0.30–1.79) 0.68
Number of cases per year for unit giving initial treatment 1 – 4 36 6 0.91 (0.355–2.34) 0.85 5 1.19 (0.59–2.40) 0.64
5 – 10 30 46 1.20 (0.46–3.16) 0.71 5 0.67 (0.32–1.43) 0.30
11 – 29 286 50 0.84 (0.54–1.32) 0.46 33 1.16 (0.59–2.28) 0.67
30 - 277 50 1 37 1
Number of cases per year for unit responsible for ending treatment 1 – 4 93 33 3.27 (1.83–5.84) <0.001 15 1.79 (0.89–3.63) 0.11
5 – 10 38 5 0.80 (0.287–2.207) 0.67 5 0.96 (0.34–2.69) 0.39
11 – 29 278 35 0.74 (0.44–1.23) 0.24 31 0.79 (0.46–1.36) 0.39
30 - 220 35 1 29 1
Treatment group standard treatment A 309 64 1 25 1
standard treatment B 54 7 0.86 (0.36–2.06) 0.73 19 5.97 (2.92–12.20) <0.001
standard treatment C 33 1 0.13 (0.018–0.99) 0.05 6 2.03 (0.76–5.41) 0.16
standard treatment D 155 24 0.72 (0.43–1.21) 0.28 16 1.22 (0.63–2.38) 0.55
other combination 9 4 0.56 (0.25–1.25) 0.16 2 5.87 (0.94–36.81) 0.06
ineffective 69 8 4.58 (1.00–21.01) 0.05 12 2.16 (1.01–4.58) 0.05
Treatment combination standard (A – D) 548 97 1 66 1
non-standard 81 11 0.78 (0.38–1.55) 0.62 14 1.46 (0.77–2.77) 0.28
Change in treatment group no 433 91 1 41 1
yes 196 17 0.40 (0.23–0.70) 0.001 39 2.05 (1.26–3.31) 0.004
Pause of treatment2 no 464 88 1 37 1
yes 157 16 0.64 (0.36–1.13) 0.14 42 3.97 (2.42–6.562) <0.001
Pause during intensive phase2 no 483 91 1 44 1
yes 134 13 0.58 (0.31–1.082) 0.09 35 3.22 (1.95–5.32) <0.001
Pause during intensive phase, due to side effect no 523 97 1 56 1
yes 106 11 0.59 (0.30–1.16) 0.13 24 2.23 (1.30–3.84) 0.005
Pause during continuation phase no 481 51 1 50 1
yes 70 8 1.49 (0.66–3.36) 0.35 22 4.18 (2.299–7.601) <0.001
NA (other + ineffective) 78
1Information missing for one case
2Information missing for 7 – 12 cases
Significant p-values are darkened.BMC Public Health 2007, 7:291 http://www.biomedcentral.com/1471-2458/7/291
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the causal relationship between tuberculosis and death.
Based on the findings of an earlier Finnish study, it is
probable that about a third of the deaths in our study were
not directly attributable to tuberculosis [33].
In our aging population of TB cases, in the absence of TB/
HIV co-infections, we found immunosuppression, virtu-
ally all due to other causes than HIV infection, from con-
comitant diseases and their medical treatment to be a risk
factor for death, as has been previously reported [7,14].
For TB deaths in persons with diseases, which are them-
selves immunosuppressive and/or require immunosup-
pressive treatment, it is frequently difficult to explicitly
determine the causal relationship between tuberculosis
and death. As the clinical presentation of the underlying
disease and TB may be difficult to differentiate, systematic
use of rapid microbiological diagnosis and the early use of
empiric treatment may be particularly valuable to
improve outcome in this patient group.
In the analysis of treatment system -related factors, we
found in univariate analysis significant or patterns of close
to significant associations to death with specialty other
than pulmonary beginning or ending the treatment, and
with a switch in the specialty responsible for treatment.
However, in multivariable analysis only the specialty serv-
ice responsible for cessation of treatment being other than
pulmonary was associated with death. Even though our
data allowed controlling for a range of comorbid states, it
is possible that in a patient population where half of the
cases are older than 65 years, there could be more comor-
bidity in the group that ends up being treated in internal
medicine and geriatric services.
An interesting finding in the univariate analysis for sys-
tem-related risk factors was a reverse association of death
with the number of cases treated per year by the unit in
charge of ending the treatment. However, this association
did not remain an independent predictor in multivariable
analysis. For other unfavourable outcomes, there was no
suggestion from univariate or multivariate analysis of an
association with number of patient treated per year. While
the volume of TB cases seen by each treating unit is
becoming small, it is relevant to observe that favourable
outcomes have been associated with increasing number of
procedures for some other medical interventions such as
treatment of leukaemia, AIDS and myocardial infarctions
[23-25]. Pulmonary medicine in Finland treats the major-
ity of tuberculosis cases, whether pulmonary or extra-pul-
monary. The experience in the treatment of tuberculosis
may therefore be greater in most pulmonary units than
other specialty services. However, the volume of cases
treated was used as a separate parameter in analysis. On
the other hand, it is possible that the patient records do
not fully cover all relevant comorbidities, which may be
more common in other services than pulmonary. That in
Table 4: Multivariate analysis of 611 cases (18 were left out due to missing values) treated at least 24 hours, odds ratio for death or 
other unfavourable (transfer out, default, physician's decision to stop early) outcomes. Reference category is favourable treatment 
outcome
Variable Death Other unfavourable
N OR (95% CI) p N OR (95% CI) p
Sex female 34 1 28 1
male 68 2.51 (1.42–4.45) 0.002 48 1.47 (0.83–2.61) 0.18
Age at diagnosis risk per five years 102 1.29 (1.16–1.42) <0.001 76 0.96 (0.88–1.041) 0.29
Immunosuppression no 74 1 72 1
yes 28 2.11 (1.12–3.97) 0.020 4 0.32 (0.097–1.062) 0.063
TB history no 96 1 73 1
yes 6 0.36 (0.133–0.97) 0.044 3 0.32 (0.087–1.16) 0.082
Specialty responsible for ending treatment pulmonary 58 1 67 1
internal medicine 16 14.08 (4.76–41.66) <0.001 4 6.89 (1.66–28.59) 0.008
general medicine 22 6.24 (3.00–12.98) <0.001 4 2.11 (0.65–6.86) 0.21
other 6 4.72 (1.46–15.33) 0.010 1 0.58 (0.060–5.68) 0.64
Pause of treatment no 86 1 36 1
yes 16 0.69 (0.33–1.47) 0.34 40 3.46 (1.92–6.27) <0.001
Treatment group standard treatment A 60 1 23 1
standard treatment B 7 0.85 (0.30–2.42) 0.76 19 5.92 (2.61–13.44) <0.001
standard treatment C 1 0.146 (0.017–1.22) 0.076 6 1.41 (0.48–4.12) 0.53
standard treatment D 24 1.42 (0.76–2.67) 0.28 15 0.94 (0.45–1.95) 0.86
other combination 8 1.15 (0.43–3.07) 0.79 11 1.54 (0.63–3.75) 0.34
ineffective 2 2.64 (0.29–24.38) 0.39 2 3.54 (0.49–25.30) 0.21
Significant p-values are darkened.BMC Public Health 2007, 7:291 http://www.biomedcentral.com/1471-2458/7/291
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part can also explain association of death with the spe-
cialty service responsible for cessation of treatment being
other than pulmonary. Overall, our results do not suggest
that outcomes would improve by concentrating treatment
in fewer clinical units in low incidence countries. This
finding is relevant for low incidence countries with rela-
tively little TB associated with immigration, homeless-
ness, drug use and imprisonment, but may not be
applicable in other settings.
Pause(s) in treatment were not found to be a risk factor for
death. This can be due to deaths concentrating in the
beginning of the treatment period in our study, leaving
less possibility for pauses. On the other hand, pauses of
treatment were a risk factor for other unfavourable out-
come both in univariate analysis and in multivariate anal-
ysis. Pauses can be caused by side effects of treatment as
well as non-compliance of a patient. There were more
pauses in the initiation phase than in the continuation
phase. Pauses during initiation may be more disadvanta-
geous than in the later phase.
The potentially protective effect of history of earlier tuber-
culosis, although of borderline statistical significance, was
an interesting finding. It seems likely that knowledge of
tuberculosis in the past raises the early suspicion of the
rare disease earlier, both in the patient as well as in treat-
ing doctor, leading to shorter delay in diagnostics and
starting treatment, reported to affect outcome [34].
For unfavourable outcomes other than death, in univari-
ate analysis association was found for being an immi-
grant, internal medicine service ending the treatment,
belonging to treatment group B (commonly used when
adverse effects necessitate switching of drugs or liver com-
plications are anticipated), change in treatment group,
and pauses in any stage of treatment. In multivariable
analysis, however, only the system-related risk factors of
internal medicine ending treatment, pause(s) and belong-
ing to treatment group B remained independently associ-
ated with other unfavourable outcome. Earlier studies
have found immigration as a significant risk factor
[7,12,16]. For analysing immigration as a risk factor in our
material, multinomial logistic regression model has a lim-
ited power, as the other unfavourable outcomes take place
very early after start of treatment. Furthermore, the
number of immigrants in this study is small, also limiting
the power in multinomial model. No association between
social risk factors and outcome was found, but that can
depend on the dominance by unemployment rather than
more extreme social issues which are rare in our country.
In a recent analysis in London imprisonment, drug use
and homelessness was found to be the most important
predictors of poor outcome [35].
Conclusion
A high proportion of deaths as TB treatment outcome are
typical in low-prevalence countries [7,9,12,15-18]. Our
results suggest that outcomes would not improve by con-
centrating treatment in fewer units with more patients.
Poor outcomes associated with immunosuppression and
advanced age, with frequent comorbidity, stress a low
threshold of suspicion, availability of rapid diagnostics,
and early empiric treatment as possible approaches in
attempting to improve treatment outcomes in countries
with very low incidence of TB.
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